Top Story


Hill Street Announces Record Revenues and Gross Profit as Strong Growth Continues

March 1st, 2023 - Ryan Allway

Toronto, ON – TheNewswire – March 1, 2023 – Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill Street” or the “Company”), a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally, is pleased to announce the following updates from the three-month period ended December 31, 2022 (“Q2 FY 2023”) financial […]

IGC Reports Financial Results for Third Fiscal Quarter Ended Dec. 31, 2022

February 14th, 2023 - Ryan Allway

POTOMAC, Md., Feb. 14, 2023 (GLOBE NEWSWIRE) — via InvestorWire — India Globalization Capital, Inc. (dba IGC, Inc.) (NYSE American: IGC) (“IGC” or the “Company”) today reported its third fiscal quarter 2023 financial results.   Third Fiscal Quarter 2023 Highlights: The Company expanded the number of sites participating in its Phase 2 clinical trial on […]

Kaya Holdings, Inc. (OTCQB:KAYS) Launches Fifth Dimension Therapeutics(TM) to seek to Provide Innovative Psychedelic-Based Treatments for Depression and Anxiety Related Conditions and address the Growing Multi-Billion Dollar Global Psychedelics Market

January 25th, 2023 - Ryan Allway

FT. LAUDERDALE, FL / ACCESSWIRE / January 25, 2023 / Kaya Holdings, Inc., (“KAYS” or the “Company”) (OTCQB:KAYS), a pioneer in the U.S. cannabis industry, announced today that it has launched Fifth Dimension Therapeutics™ (“FDT”), which will seek to provide psychedelic “mind care” treatments to veterans suffering from PTSD, addicts seeking to break addiction, individuals with […]

Israel-Based Clearmind Successfully Completed Two R&D Projects With The Hebrew University of Jerusalem’s Tech Transfer Company, Yissum

January 19th, 2023 - Ryan Allway

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of two R&D projects with leading scientists from multiple disciplines at the Hebrew University as part of a collaboration established […]

Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial

January 5th, 2023 - Ryan Allway

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced positive pre-clinical results demonstrating efficacy of its drug candidate MEAI for treating obesity and metabolic syndrome. The study, conducted at the Hebrew University […]

Clearmind Medicine Announces Shareholders Meeting Results

December 29th, 2022 - Ryan Allway

Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, is pleased to announce that all of the matters put forward before shareholders for consideration and approval at its meeting held on December 28, 2022 […]

Israeli Cannabis Technology Company BYND Cannasoft Enterprises Inc. Files EZ-G Patent Application to Include Double Faceted Condom

December 1st, 2022 - Ryan Allway

BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) (“BYND Cannasoft” or the “Company”) announced today the filing of a patent application for its EZ-G device to include an innovative double-faceted condom design. The double-faceted condom is designed to help treat various problems related to intimate relationships while making the sexual experience much more pleasurable for everyone involved. BYND […]

BioHarvest Opens the Door for Pharma Researchers to Unlock the Power of Cannabinoids

November 23rd, 2022 - Ryan Allway

The medical cannabis industry will reach more than $54 billion in size by 2029, according to Data Bridge Market Research, representing a 22.1% compound annual growth rate. In addition to patients turning to state medical cannabis programs, researchers continue to uncover evidence that cannabinoids could help treat a wide range of medical conditions. BioHarvest Sciences […]

LFTD Partners Inc. Reports Ninth Consecutive Quarter of Positive GAAP EPS

November 14th, 2022 - Ryan Allway

JACKSONVILLE, FL / ACCESSWIRE / November 14, 2022 / LFTD Partners Inc. (“LFTD Partners” or the “Company”) (OTCQB:LIFD), the corporate parent of leading cannabis and psychedelics manufacturer Lifted Made, today reported that it achieved its ninth consecutive quarter of positive earnings per share during the third quarter ended September 30, 2022, calculated in accordance with U.S. generally accepted accounting […]

BioHarvest Introduces a Breakthrough Technology That Dramatically Improves Cannabis Industry Economics

November 3rd, 2022 - Ryan Allway

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: VNVCF) is well-known for its ability to scale up trace botanical elements. For example, its flagship VINIA capsules contain the same amount of piceid resveratrol as an entire bottle of red wine with no calories, sugar, or alcohol. That’s because BioHarvest, via its technology, can increase piceid resveratrol levels […]

How CBD Could Alleviate Reproductive Health Issues & Why Investors Should Take Note

November 2nd, 2022 - Ryan Allway

Cannabidiol, better known as CBD, has a growing body of evidence suggesting it could help with everything from seizures to inflammation. While the research remains early-stage, the widespread availability of CBD and its established safety profile means anyone can experiment and see what works with limited side effects. Let’s look at how BYND Cannasoft Corp. […]

Pervasip Announces 3rd Quarter Financials

October 18th, 2022 - Ryan Allway

SEATTLE, Oct. 18, 2022 (GLOBE NEWSWIRE) — Pervasip Corp. (OTCPK: PVSP) (“Pervasip” or the “Company”), a developer of companies and technologies in high value emerging markets, today announced the filing of its unaudited financial statements for its 3rd Quarter ended August 31, 2022.   “Q3 2022 shows material signs of improvement over Q2 2022 reflecting our […]

Ultra Shear Technology: Revolutionary Process for Making the Highest Quality CBD Nanoemulsions Now Hitting the Market

October 10th, 2022 - Robin Lefferts

Cannabidiol, or CBD, and other cannabinoids are oil-based compounds. The human body is a water-based environment. To get the CBD where it needs to go, an emulsion of oil- and water-based ingredients has to be made. Emulsions can be achieved chemically or physically, and each approach has its downside. Most physical emulsions tend to separate […]

Rare Cannabinoid Company Gives Away Free THC + CBC Mood Gummies to Celebrate New Product Launch

October 9th, 2022 - Ryan Allway

Rare Cannabinoid Company announced the launch of their latest product: the world’s first hemp THC gummies with high levels of CBC for improved mood and CBD for the entourage effect.   To celebrate, the premium Hawaiian brand is giving away thousands of packets containing 10 THC gummies each, which normally cost $25. Free THC Gummies can be found […]

How CBD Could Transform Women’s Health & Wellness

October 4th, 2022 - Ryan Allway

Cannabidiol, or CBD, has become one of the world’s most popular health and wellness supplements. According to the Brightfield Group, CBD sales could reach $16 billion in the U.S. alone. A growing body of evidence suggests that CBD could be beneficial in treating many health concerns, while upcoming FDA regulations could boost public confidence. Sexual […]

Silo Pharma Announces Uplisting to Nasdaq Capital Market and Pricing of $5 Million Public Offering of Common Stock

September 27th, 2022 - Ryan Allway

Silo Pharma common stock to begin trading on Nasdaq Tuesday, September 27, 2022, under the symbol “SILO” ENGLEWOOD CLIFFS, NJ , Sept. 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (Nasdaq: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public […]

BYND Cannasoft Targets Opportunities Across the Value Chain

September 19th, 2022 - Ryan Allway

  The global cannabis market is projected to grow at a blistering 22.9% compound annual growth rate to reach $44.4 billion by 2024. With more than 30 countries having legalized either medical or adult-use cannabis, nearly 160 million people (or about 5% of the global population) consume cannabis on a regular basis for health or […]

BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28 Million

September 19th, 2022 - Ryan Allway

BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) which holds the patent pending intellectual property for a therapeutic device (the “EZ-G device”) that uses low concentrations of CBD oils, such as hemp seed oil […]

Jacksam Corporation Reports Return to Adjusted EBITDA Breakeven in the Second Quarter 2022

August 16th, 2022 - Ryan Allway

Recurring Cartridge Sales Increased 329% to $1.1 Million in the First Half 2022   NEWPORT BEACH, CA / ACCESSWIRE / August 16, 2022 / Jacksam Corporation dba Convectium (OTCQB:JKSM) (“Jacksam” or “Convectium” or the “Company”), a workflow automation Company focused on developing system solutions for the cannabis and CBD industry, today announced financial and operational results […]

Flora Growth Reports H1 2022 Financial Results

August 15th, 2022 - Ryan Allway

H1 2022 revenue increased to ~$15.0 million, up 604% from H1 2021 and 117% from H2 2021, driven by House of Brands Gross Profit increased to ~$7.0 million, up 547% compared to H1 2021 and 363% compared to H2 2021 Company reaffirms its 2022 revenue guidance to range between $35.0 million – $45.0 million, indicating […]

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

July 27th, 2022 - Ryan Allway

Silo shows reversal of allodynia and hyperalgesia using its selected formulation and partnered, patented delivery system ENGLEWOOD CLIFFS, N.J, July 27, 2022 (GLOBE NEWSWIRE) — Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia […]

Craftport Cannabis Closes $1.5 Million Private Placement

July 19th, 2022 - Ryan Allway

Peachland, British Columbia–(Newsfile Corp. – July 19, 2022) – Craftport Cannabis Corp. (CSE: CFT) (“Craftport Cannabis” or the “Company”) is pleased to announce that it has closed a non-brokered private placement offering (the “Offering”) of 18,750,000 common shares (each, a “Common Share”) at a price of $0.08 per common share for gross proceeds of $1.5 […]

Why Coca Could Become the Next Superfood (and How to Invest)

June 28th, 2022 - Ryan Allway

  Superfoods refer to nutrient-rich foods that convey positive health benefits. While catechin-rich green tea, fisetin-rich strawberries, and omega-3-rich walnuts are well-known superfoods, coca leaves remain relatively undiscovered due to their association with cocaine. But fortunately, decocainized coca leaves open the door to new possibilities. Let’s take a deep dive into the nutritional benefits of […]

New Independent Study Correlates THC in Breath and Blood using Cannabix Technology

May 16th, 2022 - Ryan Allway

The legalization of cannabis promises to solve many of society’s problems and unlock new economic opportunities. However, the move also creates new challenges for law enforcement. For instance, studies suggest that cannabis may acutely impair several driving-related skills in a dose-related fashion, but there’s no easy roadside test available. Cannabix Technologies Inc. (CSE: BLO) (OTC: […]

Why You Should Invest in Europe’s Cannabis Industry (and Its Upcoming Leader)

April 25th, 2022 - Ryan Allway

  The North American cannabis industry has struggled over the past couple of years, but fundamentals are improving and valuations are becoming attractive. As North America continues to grapple with excess supply issues, challenging margins and regulations, investors are starting to turn their attention toward European markets that are in the early innings of adoption […]

CFN Media Sits Down with Hero’s Blackbox CEO Marc Kasabasic to Discuss the Company’s Unique Technology

April 1st, 2022 - Robin Lefferts

Hero Technologies Inc. (OTC: HENC) is focused on building a vertically integrated cannabis operation in Michigan that will expand to become a multi-state operation. The company is currently in the midst of the licensing process in Michigan. In anticipation of receiving the appropriate licenses, Hero has been laying the groundwork for construction of a large […]

New Player in the Michigan Cannabis Market

March 14th, 2022 - Robin Lefferts

The state of Michigan is one of the hottest legal cannabis markets in the United States. According to Andrew Brisbo, Executive Director of Michigan’s Marijuana Regulatory Agency, the state recently passed the $3 billion dollar mark in total sales since October 2018. For 2021 alone, total sales topped $1.79 billion. The industry has been growing […]

PsyBio Therapeutics Reports Annual 2021 Financial Results

March 2nd, 2022 - Ryan Allway

OXFORD, Ohio and COCONUT CREEK, Fla., March 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health challenges, neurological disorders and other human health conditions, today announces that it […]

Revitalist Executes on Mission to Build a National Network of Ketamine Clinics

January 28th, 2022 - Ryan Allway

Psychedelics have shown tremendous promise in treating depression, anxiety, post-traumatic stress disorder, and a range of other mental health conditions. In particular, assisted psychotherapy combines psychedelic substances with talk therapy to facilitate breakthroughs and help patients that don’t see relief through conventional treatments. While psilocybin, MDMA, and other psychedelic medicines remain in clinical trials, the […]

NutraLife Accelerates Expansion into the Rapidly Growing $11 Billion CBD Industry

January 10th, 2022 - Ryan Allway

CBD has become one of the fastest-growing wellness products globally, reaching more than $11 billion in global sales last year. According to Market Data Forecast, these sales will continue to grow at a 22.2% annual pace to nearly $31 billion by 2026. As a result, companies building an early presence in the industry could be […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading